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ABSTRACT 
The increasing prevalence of type 2 diabetes mellitus (T2DM) poses a major threat to 
the health and well-being of South Africans. Effective interventions to inform health 
planning and policy are hampered by the paucity of accurate national epidemiological 
data. Although several prevalence studies have been conducted, these estimates are 
not representative of the South African population or are sub-optimal due to the 
diagnostic methods employed. To address the lack of accurate and representative 
prevalence data, the aim of this dissertation is to use robust systematic review 
methods to collate, synthesise and summarise all T2DM prevalence data in South 
Africa.  
 
The dissertation comprises of four parts. Part A contains the study protocol that was 
published in BMJ Open in 2018. The protocol outlines the problem statement, 
motivation and rationale, aim, search strategy and robust systematic methods that 
were used to conduct the study. Part B provides an overview of T2DM enabling a 
broader understanding of the disease, with a focus on South Africa and the challenges 
of obtaining accurate T2DM prevalence estimates. We also describe prevention and 
management strategies for T2DM, and point to priority actions and approaches to 
achieve such prevention and management of T2DM. Part C consists of a manuscript 
that has been formatted for submission to BMJ Open and Part D is an Appendix with 
supporting information. This part addresses the aim of the dissertation and presents 
the systematic review “The prevalence of type 2 diabetes in South Africa: A systematic 
review”. The manuscript outlines the rationale and methodologies, together with 
presenting and discussing the results of the systematic review. Our literature search, 
which included PubMed, Scopus, Web of Science and African Index Medicus, grey 
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literature and references of included studies identified 1782 articles published in South 
Africa between January 1997 and May 2019. Of these, 15 met the inclusion criteria 
and were included in the systematic review. Heterogeneity across studies did not allow 
for a meta-analysis and a pooled estimate, thus results are described narratively. 
Some studies failed to report key methodological elements, which limited our ability to 
accurately appraise study quality. In conclusion, the systematic review highlights the 
high prevalence of glucose intolerance in South Africa and confirms the paucity of 
accurate and representative T2DM prevalence data. There is a need for well-designed 
epidemiological studies that use best-practice, uniform diagnostic methods to assess 
prevalence. Collaboration between public health scientists, diabetes specialists and 
policy makers is recommended to enable the collection of reliable national 
epidemiological data which can guide policy and planning towards effective diabetes 
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Type 2 diabetes mellitus is a major source of morbidity and mortality in South Africa, 
spurred by increased urbanisation and unhealthy lifestyle factors. Local 
epidemiological data are required to inform health planning and policy. The purpose 
of this systematic review is to identify, collate and synthesise all studies reporting the 
prevalence of diabetes in South Africa. A secondary aim is to report the prevalence of 
impaired glucose tolerance and impaired fasting glucose, conditions which are 
associated with an increased risk of progression to overt diabetes, and the prevalence 
of undiagnosed diabetes. 
 
Methods and analysis 
Multiple databases will be searched for diabetes prevalence studies conducted in 
South Africa between 1997 and 2018. Two authors will independently select studies 
that meet the inclusion criteria, extract data and appraise studies using a risk of bias 
tool for prevalence studies. Studies with low or moderate risk of bias will be included. 
Sources of heterogeneity will be explored using subgroup analysis. 
 
Ethics and dissemination 
The systematic review does not require ethics clearance since published studies with 
non-identifiable data will be used. This review will provide best estimates to inform the 
Second National Burden of Disease study which can guide health and policy planning. 
PROSPERO registration number: CRD42017071280 
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2. STRENGTHS AND LIMITATIONS  
• The first ever systematic review of type 2 diabetes prevalence in South Africa. 
• A comprehensive synthesis of all available diabetes prevalence data in South 
Africa using a standardised risk of bias tool.  
• The protocol adheres to Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses Protocols guidelines.  
• The quality of the review will be assessed using the Grading of Recommendations 
Assessment, Development and Evaluation. 
• The heterogeneity in diagnostic criteria, study dates, age of study participants and 
population groups may limit comparison across studies. 
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3. INTRODUCTION 
Diabetes mellitus, a condition characterised by raised blood glucose levels, is a major 
source of morbidity, mortality and health costs worldwide. The International Diabetes 
Federation estimates that in 2017, 451 million adults aged between 20-79 years 
worldwide had diabetes, with projections of 693 million cases by 2045. Globally, 
approximately 50% of diabetes cases are undiagnosed, with the majority of these 
occurring in low-income and middle-income countries. In Africa, the proportion of 
undiagnosed diabetes is 69.2%. Furthermore, 77% of deaths due to diabetes in Africa 
occurred in individuals younger than 60 years of age, emphasising the magnitude of 
the diabetes epidemic, and the urgency to intervene effectively to reduce premature 
mortality [1]. In Africa, as in other parts of the world, type 2 diabetes represents over 
90% of diabetes cases [2,3]. 
 
The prevalence of diabetes is rapidly increasing in South Africa. In 2009, 
epidemiological modelling estimated a diabetes prevalence of 9% (2 million) in people 
aged 30 years and older [4], increasing almost twofold since 2000 when Bradshaw et 
al estimated a prevalence of 5.5% in the same age group [5]. Several factors such as 
the ageing population, economic transition and urbanisation associated with the 
nutrition transition and being overweight and/or obese have contributed to the 
increased diabetes prevalence [6–9]. In 2000, it was estimated that 87% of the type 2 
diabetes burden in South Africa is attributed to excess body weight [10]. This is 
concerning since in 2013, ~38% of men and ~69% of women in South Africa were 
considered overweight or obese [11]. In 2015, the global burden of disease study 
estimated that high body mass index and hyperglycaemia, ranked as the second and 
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third leading risk factors, respectively, after unsafe sex, for early death and disability 
in South Africa [12].  
 
Diabetes, due to its association with several microvascular and macrovascular 
complications, places a significant burden on the South African health system. In 2009, 
it was estimated that diabetes caused about 8000 new cases of blindness and 2000 
new cases of amputations annually [4]. A national burden of disease study in 2000 
reported that, among adults 30 years and older, diabetes accounted for approximately 
14% of ischaemic heart disease, 10% of stroke, 12% of hypertensive disease and 12% 
of renal disease burden [5].  
 
Furthermore, the indirect costs of diabetes are high. Diabetes in Africa affects mainly 
working-aged people between 40 and 60 years of age [9], placing an added burden 
on the economy due to work absenteeism and decreased productivity. South Africa is 
battling a quadruple burden of disease due to high rates of infectious diseases, non-
communicable disease, maternal and child mortality, and injury-related conditions, 




Urgent action is required to halt the burgeoning diabetes epidemic in South Africa. The 
feasibility of population-level interventions, particularly those aimed at prevention are 
widely reported [14]. However, such initiatives are hampered by the lack of 
epidemiological data, a challenge faced by all countries in Africa [15]. Several studies 
have measured the prevalence of diabetes in South Africa [16–26], although they were 
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conducted in different geographical areas (urban vs rural), among different population 
groups and are generally too small to individually give generalisable prevalence data. 
Pooling of existing data is considered an effective strategy to generate representative 
and robust prevalence figures [8]. Bertram et al calculated the national prevalence of 
diabetes in 2009 [4]; however, their estimate included only four studies measuring the 
diabetes prevalence in black South Africans in two rural, one urban and one metro 
urban population [21–24]. The study did not account for population-group variation in 
diabetes prevalence in South Africa [16,19,20,23], and focused on estimating the 
disability burden of diabetes rather than characterising the different levels of 
hyperglycaemia in these populations. This review explores availability and quality of 
diabetes prevalence data for South Africa. 
 
5. OBJECTIVE 
The purpose of this systematic review is to identify, collate and synthesise all studies 
reporting the prevalence of diabetes in South Africa. A secondary aim is to report the 
prevalence of impaired glucose tolerance and impaired fasting glucose, conditions 
which are associated with an increased risk of progression to overt diabetes, and the 
prevalence of undiagnosed diabetes. These findings will be used to inform the Second  
National Burden of Disease study which can guide health and policy planning. 
 
6. METHODS 
6.1 Study selection 
Published population-based surveys, cross-sectional studies and prospective or 
retrospective cohort studies that report the prevalence of diabetes in South Africa. 
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6.2 Inclusion criteria 
Studies will be included if they were published between January 1997 and 
February 2018, include more than 100 participants regardless of age, gender, 
ethnicity, socioeconomic and educational background and study setting, and report 
the primary outcome using a case definition according to the 1999 WHO diagnostic 
criteria [27], where type 2 diabetes is diagnosed either by a physician, fasting blood 
glucose concentrations ≥7.0 mmol/L, 2-hour oral glucose tolerance test values ≥11.1 
mmol/L or self-reported use of oral diabetes drugs. In addition, glycated haemoglobin 
≥6.5% (48 mmol/mol) will also be used for case definition [28]. Due to limitations that 
hamper the differentiation between type 1 diabetes and type 2 diabetes, diabetes in 
individuals older than 25 years of age will be classified as type 2 diabetes. Impaired 
glucose tolerance will be defined by fasting blood glucose concentrations <7.0 mmol/L 
and 2-hour oral glucose tolerance values ≥7.8 mmol/L, but <11.1 mmol/L. Impaired 
fasting glucose will be defined as fasting blood glucose concentrations between 6.1 
mmol/L and 6.9 mmol/L, and, if available, 2-hour oral glucose tolerance values <7.8 
mmol/L [27]. Undiagnosed diabetes is defined as the number of new cases of diabetes 
as a proportion of the total sample.  
 
6.3 Exclusion criteria 
Studies will be excluded if they were not conducted in South Africa, do not report the 
primary outcome, have no clear description of the case definition, and contain data for 
refugees in camps since they may not be representative of the South African 
population. 
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6.4 Primary outcome 
Prevalence of type 2 diabetes. 
 
6.5 Secondary outcome 
Prevalence of impaired glucose tolerance, impaired fasting glucose and undiagnosed 
type 2 diabetes. 
 
6.6 Search strategy 
A search of articles written in English and indexed in PubMed, Scopus, Web of Science 
and African Index Medicus between January 1997 and February 2018 will be 
conducted. An experienced information scientist and disease content experts will be 
consulted to ensure that the search terms are relevant and optimally arranged, and 
will include keywords and medical subject headings. An example of the search 
strategy in PubMed is illustrated in Table 1. The search will be modified to each 
database. References will be managed in EndNote. 
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Table 1. PubMed search strategy   
Search Query 
#4 Search ((#3 NOT (animals[mh] NOT humans[mh]))) AND 
(“1997/01/01”[Date-Publication] : “2018/02/28”[Date-Publication]) 
#3 Search (#1 AND #2) 
#2 Search (South Africa[mh]OR“South Africa*”[tiab] OR RSA[tiab] OR Africa, 
Southern[mh:noexp] OR Southern Africa[tiab]) 
#1 Search (Diabetes[Mesh] OR Diabetes mellitus[Mesh] OR type 2 diabetes 
mellitus[Mesh] OR type 2 diabetes[Mesh] OR Diabetes mellitus, type 
2[Mesh] OR Diabetes, type 2[Mesh] OR hyperglycemia[Mesh] OR blood 
glucose[Mesh] OR Hemoglobin A, glycosylated[Mesh] OR Glycosylated 
hemoglobin OR diagnosis OR impaired glucose tolerance OR impaired 
fasting glucose OR undiagnosed diabetes 
 
 
6.7 Study selection  
The titles and abstracts of articles from the electronic search outputs will be screened 
independently by two reviewers to identify eligible studies. Disagreements or 
uncertainties will be resolved by discussion and consensus between the two 
reviewers, or with a third reviewer if disagreement persists. Full-text copies of the 
eligible articles will be retrieved and reviewed by two independent reviewers for 
inclusion. Additional information will be requested from the study authors if required. 
Reasons for exclusion will be recorded.  
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6.8 Data extraction 
After the final decision to include studies into the review, two authors will independently 
extract and record data using the Burden of Disease (BOD) Review Manager 
developed by the Burden of Disease Research Unit of the South African Medical 
Research Council [29]. The following data will be extracted:  
• Study details: date of publication, study title, study design, study period and study 
purpose.  
• Study population: province/district of study, study setting (community or health 
facility based), residential setting (urban or rural) and sample size.  
• Response rate. 
• Case definition as reported in the study.  
• Prevalence of type 2 diabetes, impaired glucose tolerance, impaired fasting glucose 
and undiagnosed type 2 diabetes. 
• Characteristics of study population: age, sex, population group (ethnicity) and 
comorbid disease (tuberculosis (TB) or human immunodeficiency virus (HIV) 
status). 
After completion, data will be compared and discrepancies will be resolved through 
consensus between the two reviewers, or in consultation with a third reviewer. 
 
6.9 Risk of bias assessment  
Two reviewers will independently appraise the study quality and risk of bias using a 
checklist for observational epidemiological studies that was adapted from the risk of 
bias tool for population-based studies [30] and the Newcastle-Ottawa Scale for 
assessing the quality of non-randomised studies [31,32], and standardised in the BOD 
Review Manager [29]. Parameters assessed will include: external validity (whether the 
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target population is representative of South Africa, representativeness of sample, 
selection criteria and non-response bias) and internal validity (case definition, validity 
and reliability of test instruments, consistency of case measurement, appropriateness 
of time period, and appropriateness of numerators and denominators in estimation). 
Disagreements between the reviewers over the risk of bias will be resolved by 
discussion with a third review reviewer where necessary. 
 
6.10 Data synthesis 
A narrative description will be conducted for studies with a low or moderate risk of 
bias. Clinical heterogeneity will be investigated by looking at the characteristics of 
participants, method of diagnosis and case definitions in the study. Subgroup analyses 
for study population (province/district, community or health facility based, urban or 
rural) and characteristics of cases (age, sex, population group, and comorbid disease 
TB or HIV) will be done if sufficient data exists. If possible, a meta-regression to 
explore possible sources of variability in prevalence reported between studies will be 
conducted. Review findings will be displayed using tables and forest plots as 
appropriate. 
 
6.11 Confidence in cumulative evidence 
The strength of evidence will be assessed using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) method [33], which scores 
studies as very low, low, moderate, or high based on methodological flaws within the 
included studies, consistency of results across diverse studies, precision of estimates 
and publication bias.  
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6.12 Patient and public involvement 
Patients and the public were not involved. 
 
6.13 Ethics and dissemination 
The systematic review does not require ethics clearance since published studies with 
non-identifiable data will be used. This review is the first to collate and synthesise all 
the available studies reporting the prevalence of diabetes in South Africa and will 
provide local epidemiological data to inform the Second National Burden of Disease 
study, which can guide health and policy planning. Findings from the review will be 
disseminated in a peer-reviewed journal article and academic reports according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 
guidelines). The protocol is published adhering to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines (Part D-
Appendix) [34].  
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1. INTRODUCTION 
Diabetes mellitus is a public health crisis and a significant cause of morbidity and 
premature mortality decreasing life expectancy by 7-15 years (Ali et al., 2017). In 2017, 
the International Diabetes Federation (IDF) estimated that 15.5 million people between 
the ages of 20 and 79 years in sub-Saharan Africa had diabetes. This number is 
expected to increase to 40.7 million people by 2045 (International Diabetes 
Federation, 2017). Projections are that sub-Saharan Africa will have the greatest 
increase globally (International Diabetes Federation, 2017), where the adverse health 
and economic effects will be devastating. Prevalence and mortality rates of type 2 
diabetes mellitus (T2DM), which accounts for over 90% of diabetes cases, have 
steadily increased in South Africa (Peer et al., 2012; Pillay-van Wyk et al., 2016), a 
country with an already overburdened and under-resourced health system.   
 
Reliable epidemiological data are important to guide health policy and planning 
towards developing effective interventions to prevent and manage T2DM. Data 
modelling have been used to estimate national prevalence (Bradshaw et al., 2007; 
Bertram et al., 2013), and although these studies used robust methods, their estimates 
probably underestimate the disease burden due to limitations of the included studies, 
which were of small size, non-representative and represented an earlier time period. 
Two national surveys in 2012 (Shisana et al., 2014) and 2016 (National Department 
of Health et al., 2019) measured T2DM prevalence, however, these were based on 
self-report and glycated haemoglobin (HbA1c), methodologies with limitations in the 
South African population (Zemlin et al., 2011; Oni et al., 2017).  
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The aim of the literature review is to provide an overview of T2DM epidemiology in 
South Africa, enabling deeper insight into the disease and highlighting the challenges 
of measuring accurate prevalence data.  
 
2. DIABETES MELLITUS  
Diabetes mellitus is a chronic metabolic disease characterised by hyperglycaemia due 
to defects in insulin secretion, insulin action or a combination of both (Karamanou et 
al., 2016). Mortality directly attributed to diabetes is listed amongst the top ten causes 
of deaths globally (WHO, 2017) and in South Africa (Pillay-van Wyk et al., 2016). 
Furthermore, diabetes is associated with both microvascular (retinopathy, neuropathy 
and nephropathy) and macrovascular (cardiovascular diseases) complications, 
increased susceptibility to infections and slow wound healing. In 2015, hyperglycaemia 
was ranked as the third leading risk factor for death and disability in South Africa (GBD 
2015 Risk Factors Collaborators, 2016). Diabetes mellitus is a complex disease with 
multiple aetiologies, which are broadly divided into different types.    
 
2.1 Type 1 diabetes  
Type 1 diabetes mellitus (T1DM), which accounts for approximately 5-10% of diabetes 
cases worldwide (American Diabetes Association, 2013), occurs due to the failure of 
pancreatic beta (β) cells to produce insulin and is often diagnosed in younger 
individuals. Genetic predisposition is considered the major cause of T1DM, although 
in recent years the role of environmental factors in T1DM aetiology has been 
suggested (Rewers & Ludvigsson, 2016).  
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2.2 Type 2 diabetes  
Type 2 diabetes mellitus (T2DM) is undeniably the major driver of the diabetes 
epidemic, accounting for 90-95% of diabetes cases (American Diabetes Association, 
2013). It is a complex, progressive disease that primarily occurs due to the inability of 
the body to respond to insulin, a condition referred to as insulin resistance (Kahn, Hull 
& Utzschneider, 2006). With time, pancreatic beta (β) cells become dysfunctional, 
insulin secretion decreases and hepatic glucose production increases leading to 
postprandial and fasting hyperglycaemia (Figure 1) (Ramlo-Halsted & Edelman, 
1999). Complications can manifest up to 10 years before clinical diagnosis, thus the 
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2.3 Other types of diabetes 
Gestational diabetes mellitus (GDM), which is defined as hyperglycaemia that is first 
detected during pregnancy that is not T1DM nor T2DM (World Health Organization, 
1999) is receiving renewed interest worldwide, partly due to the increased risk of 
T2DM in mothers and children (Damm, 2009) and because it presents an ideal 
opportunity to alter T2DM trajectory (Buyken et al., 2010). It is estimated that up to 
14% of pregnancies worldwide are complicated by GDM, although rates vary 
according to diagnostic criteria and ethnicity (International Diabetes Federation, 2017). 
Maturity onset diabetes of the young (MODY) is a heterogeneous group of disorders 
where genetic mutations cause diabetes primarily through their effects on β-cell 
dysfunction (Gardner & Tai, 2012). Other less common forms of diabetes include 
genetic defects of insulin action, diseases of the pancreas, and diabetes induced by 
drugs or infections (American Diabetes Association, 2013).  
 
2.4 Impaired glucose tolerance and impaired fasting glucose 
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are commonly 
referred to as prediabetes (Figure 1) and represent intermediate states of dysregulated 
glucose homeostasis that precede clinical diagnosis of T2DM (Nathan et al., 2007). 
Individuals with prediabetes have a 5-12 times higher annual risk of developing T2DM 
compared to the general population (Gerstein et al., 2007). Different 
pathophysiological mechanisms underlie prediabetes. IGT is thought to occur due to 
muscle insulin resistance, IFG due to hepatic insulin resistance, while individuals with 
both IGT and IFG manifest both muscle and hepatic insulin resistance (Nathan et al., 
2007).  
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3. TYPE 2 DIABETES BURDEN 
3.1 Global  
A pooled analysis from 751 population-based studies that measured fasting plasma 
glucose (FPG) concentrations and included 4,372,000 adults from 146 countries, 
reported that the global age-standardised T2DM prevalence in adults 18 years and 
older increased from 5.0% in 1980 to 7.9% in 2014 in females and 4.3% to 9.0% in 
males (NCD Risk Factor Collaboration, 2016). This prevalence is similar to the 8.8% 
prevalence estimated by the IDF, albeit their estimates were calculated from studies 
that included self-report, medical records, different age ranges (i.e. 18 years and older 
compared to 20-79 years as reported by IDF) and/or biomarkers (International 
Diabetes Federation, 2017). Deaths due to T2DM increased by 43.0%, largely due to 
population growth and ageing, while age-standardised death rates increased by 5.9% 
between 2007 and 2017 (Roth et al., 2018).  Global health expenditure on people with 
diabetes aged 20-79 years is estimated at 727 billion USD (United States Dollars), 
increasing more than 3-fold since 2007 (International Diabetes Federation, 2017). 
Similarly, indirect costs due to decreased productivity and economic activity, and 
societal costs are high. Although historically considered a disease of developed 
nations, urbanisation and demographic and epidemiological transition have increased 
the burden of T2DM in low- and middle- income countries (LMICs) also.  
 
3.2 Africa  
The IDF estimates that the prevalence of T2DM in Africa will increase more than 2.6-
fold over the next 25 years, the highest projected increase of T2DM globally 
(International Diabetes Federation, 2017). It is estimated that 69.2% of diabetes cases 
in Africa are undiagnosed, reflecting low awareness, inadequacies in health systems 
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and limited access to care. Approximately 80% of diabetes deaths in Africa occur in 
the economically active group (individuals younger than 60 years of age), thus 
diabetes is a significant cause of indirect economic (decreased productivity due to 
absenteeism and suboptimal work performance) and intangible (psychosocial harm) 
costs.   
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3.3 South Africa 
South Africa is ranked as an upper-middle income country (World Bank, 2014) and the 
second largest economy in Africa. Despite this, it is plagued by high economic and 
health inequalities due to years of racial and gender discriminatory policies, which 
have led to a sub-optimal health system with health outcomes often worse than those 
in poorer countries (Coovadia et al., 2009). South Africa has a unique quadruple 
disease burden characterised by high rates of Human Immunodeficiency 
Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and Tuberculosis (TB), non-
communicable diseases, maternal and childhood mortality, and injury-related 
disorders (Mayosi et al., 2009). Epidemiological modelling demonstrated that the 
prevalence of T2DM has almost doubled from 5.5% in 2000 to 9% in 2009 (Bradshaw 
et al., 2007; Bertram et al., 2013). More recent studies, although not nationally 
representative, report an age-adjusted prevalence of 13.1% (Peer et al., 2012) or 
26.3% (Erasmus et al., 2012) depending on population group. Furthermore, these 
studies report a high prevalence of IGT and undiagnosed diabetes (11.2% and 4.9%, 
respectively (Peer et al., 2012) and 15.3% and 18.1%, respectively (Erasmus et al., 
2012)), indicating a high overall burden of glucose intolerance. A community-based 
study reported that the prevalence of T2DM and IGT increased approximately 60% 
between 1990 and 2008/2009 (Peer et al., 2012), while national diabetes mortality 
rates increased by 29% between 1997 and 2012 (Pillay-van Wyk et al., 2016). This 
increase is most probably continuing, as risk factors of T2DM have significantly 
increased in recent years. Furthermore, T2DM increases the risk for microvascular 
and macrovascular complications. In 2009, it was estimated that diabetes accounted 
for about 8000 new cases of blindness and 2000 new cases of amputations annually 
in South Africa (Bertram et al., 2013), while 14% of ischaemic heart disease, 10% of 
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stroke, 12% of hypertensive disease and 12% of renal disease in South Africa was 
attributed to diabetes in 2000 (Bradshaw et al., 2007). 
 
3.3.1 Type 2 diabetes risk factors  
Both modifiable and non-modifiable risk factors for T2DM such as obesity and ageing 
have increased in sub-Saharan Africa (Peer et al., 2014; Atun et al., 2017), with 
urbanisation and population ageing arguably the biggest culprits. Urbanisation is 
associated with the adoption of unhealthy lifestyles characterised by energy-dense 
diets and physical inactivity. South Africans are considered to be among the most 
overweight and obese people globally, with 69% of women and 39% of men 
overweight or obese (Ng et al., 2014), while 87% of T2DM cases in South Africa are 
attributable to excess body weight (Joubert et al., 2007). A study conducted in black 
Africans about 30 years ago, reported that urbanisation is associated with a 2.3-fold 
increased likelihood of developing diabetes (Levitt et al., 1993). Alarmingly, 
urbanisation rates for this population group has steadily increased since then (Kok and 
Collinson, 2006). Population ageing, due to the improvement in health systems and 
access to care, increases the total burden of T2DM in the population (Peer et al., 
2014). Other risk factors include genetics (Yako et al., 2016), population group self-
identified as “Indian” (Shisana et al., 2014; National Department of Health et al., 2019), 
female gender (Peer et al., 2012; Hilawe et al., 2013), sedentary lifestyles, harmful 
alcohol consumption, low levels of education, impaired psychological state and 
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3.3.2 Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome  
         and Tuberculosis 
The impact of HIV/AIDS and TB on the T2DM epidemic in South Africa, a country with 
a high prevalence of these infectious diseases is concerning (Human Sciences 
Research Council, 2018). The widespread implementation and success of 
antiretroviral treatment (ART) programmes and TB treatment have significantly 
increased life expectancy of those living with HIV/AIDS and TB and contributed to 
population ageing and risk for T2DM (Rehle et al., 2015; Non, Escota & Powderly, 
2017). Moreover, interactions between these infectious diseases and T2DM 
exacerbate each other. Both HIV infection and ART is associated with premature 
ageing and metabolic dysfunction (Lagathu et al., 2017) and increases T2DM risk 
(Non, Escota & Powderly, 2017; Pepin et al., 2018), while interactions between 
diabetes and TB are common and exacerbate disease burden (Noubiap et al., 2019).  
 
4. TYPE 2 DIABETES DIAGNOSIS  
Diagnostic criteria for T2DM have evolved over the last few decades, although 
measurement of glucose concentrations has remained the cornerstone (Polonsky, 
2012). Glucose concentrations are measured in whole blood, serum or plasma, with 
venous plasma recommended by the National Academy of Clinical Biochemistry and 
the American Diabetes Association (ADA) (Sacks et al., 2002, 2011) and the most 
commonly used method. The diagnostic criteria are illustrated in Table 1, although the 
preferred test and the one best able to predict long-term microvascular and 
macrovascular disease is still not conclusive (World Health Organization, 2006, 2011; 
American Diabetes Association, 2013). Clinical diagnosis of diabetes requires two 
abnormal glucose measurements or one abnormal glucose measurement in the 
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presence of symptoms such as increased thirst and urine production, blurring of vision 
and weight lost. Acute infections, trauma and stress may lead to transient 
hyperglycaemia; thus, an additional confirmatory test is required for asymptomatic 
individuals (Alberti & Zimmet, 1998).  
 
4.1 Oral glucose tolerance test 
The oral glucose tolerance test (OGTT) measures glucose concentrations two hours 
after ingestion of a 75-g glucose load following an eight-hour fast. The OGTT is the 
gold standard for T2DM diagnosis and is the only test able to detect impaired insulin 
function, the major pathophysiology of T2DM (Cox & Edelman, 2009). The OGTT is 
resource-intensive in terms of health care personnel, costs, time, necessity of fasting 
and requires an additional clinic visit to obtain results, limiting its use. In some 
instances, the OGTT has shown poor reproducibility due to intra-individual 
heterogeneity (Mooy et al., 1996; Ko et al., 1998).  
 
4.2 Fasting plasma glucose 
The FPG test measures glucose concentrations after fasting for at least eight hours 
and is the most commonly used test due to pragmatic reasons. Although, more 
convenient and less time consuming than the OGTT, measuring FPG still requires 
overnight fasting, a return clinic visit to obtain results, and has poor sensitivity 
compared to OGTT (Cox & Edelman, 2009), probably reflecting different disease 
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4.3 Glycated haemoglobin 
In 2009 the ADA recommended the use of glycated haemoglobin (HbA1c) as an 
alternative diagnostic test, which was later adopted by the World Health Organization 
(WHO) (International Expert Committee, 2009; World Health Organization, 2011). 
Glycated haemoglobin is formed by the binding of glucose to haemoglobin and reflects 
glycaemic control over a three-month period. The HbA1c test is gaining popularity 
since it can be conducted in a non-fasted state, is less time consuming than the OGTT 
and is a good indicator of chronic hyperglycaemia and long-term complications. 
However, the accuracy of the test is affected by ethnicity, haemoglobinopathies, red 
blood cell disorders and anaemia (Zemlin et al., 2011).  
 
Table 1. Type 2 diabetes diagnostic criteria 
 WHO criteria ADA criteria 
Type 2 diabetes 
Fasting plasma glucose 
Two-hour OGTT glucose 
HbA1c 
 
≥ 7.0 mmol/L 
≥ 11.1 mmol/L 
≥ 6.5 % (48 mmol/L) 
 
≥ 7.0 mmol/L 
≥ 11.1 mmol/L 
≥ 6.5 % (48 mmol/L) 
Impaired glucose tolerance* 
Fasting plasma glucose 
Two-hour OGTT glucose 
HbA1c 
 
< 7.0 mmol/L 
≥ 7.8 & < 11.1 mmol/L 
N/A 
Fasting: ≥ 5.6 & < 7.0 
mmol/L 
Two-hour: ≥ 7.8 & < 
11.1 mmol/L 
HbA1c: 5.7 - 6.4 % 
 
Impaired fasting glucose* 
Fasting plasma glucose 
Two-hour OGTT glucose 
HbA1c 
 
≥ 6.1 & < 7.0 mmol/L 
< 7.8 mmol/L 
N/A 
 
*Impaired glucose tolerance and impaired fasting glucose are referred to as 
prediabetes by the American Diabetes Association.   
HbA1c, Glycated haemoglobin; OGTT, Oral Glucose Tolerance Test 
(World Health Organization, 1999, 2011; American Diabetes Association, 2013) 
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4.4 Point-of-Care diagnosis 
In recent years, point-of-care testing has attracted interest for the diagnosis of T2DM 
due to its many advantages, which include convenience, use of fingerprick blood, 
immediate results and decision-making without the need for repeated visits (Vučić 
Lovrenčić et al., 2013). Although several studies have reported that point-of-care tests 
offer potential, their clinical applicability has not been satisfactorily demonstrated and 
measurement of glucose concentrations in an accredited laboratory is still 
recommended by the National Academy of Clinical Biochemistry and the ADA (Sacks 
et al., 2011).  
 
4.5 Dried blood spots 
Dried blood spots (DBS), which are obtained by allowing a few drops of capillary blood 
collected via finger prick to absorb onto filter paper, have garnered interest as an 
alternative to venous blood for HbA1c testing (Affan et al., 2014).  Attaining DBS is 
more cost effective and acceptable to study participants, safer, requires less training 
of staff and is logistically easier to store and transport than venous blood. Studies 
comparing DBS to venous blood samples have shown the potential of DBS to serve 
as a proxy for venous blood, although lack of standardisation of sample collection, 
transportation, storage and analysis, prevent its clinical use at present (Affan et al., 
2014; Mastronardi et al., 2015).  
 
4.6 Challenges of measuring type 2 diabetes prevalence  
The complex pathophysiology of T2DM, together with the variation in diagnostic 
methods and criteria, negatively impacts the ability to accurately assess the 
prevalence of T2DM (Danaei et al., 2015). These inadequacies, which are particularly 
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evident in sub-Saharan Africa, contribute to the inaccuracy of global T2DM estimates 
and the lack of an estimate on the “true” burden of T2DM. Organisations such as the 
NCD Risk Factor Collaboration, IDF and GBD calculate global estimates based on 
data pooled from country-specific prevalence data, which are often lacking or of poor 
quality. To obtain estimates for countries without prevalence data, the IDF extrapolates 
data from other nations with similar characteristics (such as demography), although 
some of these extrapolations are inappropriate due to ethnic and socio-economic 
reasons (Zimmet et al., 2016). The validity of global T2DM estimates is further 
hampered by the challenges of measuring prevalence, which include misdiagnosis 
due to measurement error of diagnostic tests, and sampling and reporting bias as 
illustrated in Table 2. Alarmingly, these national and global estimates are confidently 
used by the scientific community for reporting and decision-making. Furthermore, 
there is a paucity of estimates on IGT, largely due to challenges of the OGTT, the only 
test able to diagnose IGT. IGT is a significant predictor of future T2DM thus these 
estimates are critical to assess the total burden of glucose intolerance and for 
implementing effective interventions (Gerstein et al., 2007). Using OGTT, although 
considered more accurate to detect diabetes cases, may reduce response rate, hence 
increase sampling bias, especially in large-scale surveys. This is one of the main 
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Table 2. Challenges of measuring type 2 diabetes prevalence in epidemiological studies 
 
Challenge Reason 
Measurement error (sensitivity, accuracy and reliability of diagnostic tests) 
Non-standardisation of diagnostic method 
Studies use different diagnostic tests with different sensitivities and specificities (Danaei et al., 2015; 
Kengne et al., 2017), reflecting the complexity and multiple pathophysiologies of T2DM. 
Poor performance of FPG compared to OGTT 
FPG misses a significant number of diabetes cases compared to OGTT (Werfalli et al., 2016; Kengne 
et al., 2017). This has important ramifications for global diabetes monitoring since the WHO 
STEPWise approach to surveillance (STEPS) recommends using FPG (WHO, n.d.). 
Poor performance of HbA1c compared to OGTT 
The performance of the test is affected by ethnicity and haemoglobinopathies, which are common in 
Africa. The development of population-specific cut-offs is required (Zemlin et al., 2011). 
Incorrect cut-offs  
 
The application of incorrect cut-offs may underestimate or overinflate the prevalence of T2DM (Taylor 
et al., 2016), with important ramifications for global diabetes monitoring (Bennett et al., 2017; Ezzati 
et al., 2017). 
Pre-analytical and analytical variation  
 
Quality assurance is not applied to many epidemiological studies, while delays in sampling handling, 
plasma separation and measurements could affect diagnosis due to the instability of glucose in blood 
samples (Alberti & Zimmet, 1998; Zimmet et al., 2016). 
Non-fasted state  
 
The OGTT and FPG requires fasting prior to testing. Fasting is difficult to measure and poses a 
limitation, particularly in epidemiology surveys where participants may not be as committed to fasting 
as in a clinical setting (Maimela et al., 2016; Zimmet et al., 2016). 
Self-report  
 
Accuracy of self-report ranges between 64% to 98% in developed countries. In Africa, these are 
expected to be lower due to high rates of undiagnosed diabetes and stigmatisation (Margolis et al., 
2008; Peer et al., 2014). 
Error due to sampling and reporting bias  
Inaccurate estimates  
 
Sampling bias due to convenience and non-random sampling, age-related demographical factors, 
etc. (Atun et al., 2017). 
Transient hyperglycaemia   
 
Diabetes is diagnosed using a single abnormal glucose measurement, thus transient hyperglycaemia 
due to other conditions may incorrectly be diagnosed as T2DM (Alberti & Zimmet, 1998). 
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5. PREVENTION AND MANAGEMENT OF TYPE 2 DIABETES  
5.1 Prevention of type 2 diabetes  
The health and economic costs of preventing T2DM are considerably more favourable 
than managing the disease and its complications (Ali et al., 2017). Interventions 
targeting modifiable risk factors are effective. Improving diet and physical activity have 
been shown to prevent T2DM (Knowler et al., 2002; Unwin & Alberti, 2006), particularly 
in high risk groups (IGT and IFG) (Orozco et al., 2008). We eagerly await the results 
of a lifestyle intervention study conducted in Pretoria, South Africa (Pengpid, Peltzer 
& Skaal, 2014) to determine whether simple population-level interventions aimed at 
improving health literacy, raising public awareness about the signs and symptoms of 
T2DM and promoting healthier lifestyles are able to prevent T2DM in South Africa.  
 
5.2 Lifestyle interventions to treat type 2 diabetes  
Lifestyle modification is the recommended first-line treatment for newly diagnosed 
patients (Lakhtakia, 2013). This involves increasing awareness about T2DM risk 
factors and educating patients about the importance of a healthy diet, physical activity 
and the harmful effects of smoking and alcohol abuse. Well-structured educational 
programs for both health care providers and patients have shown success in 
controlling T2DM (Ali et al., 2017). Unfortunately, lifestyle modifications are difficult to 
adhere to because of the high costs of healthy eating, barriers to physical activity and 
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5.3 Pharmacological management  
Several classes of antidiabetic drugs are available for treating T2DM. Metformin 
monotherapy is the recommended first-line antidiabetic treatment. Other drugs 
(Sulphonylureas, Meglitinides, Alpha-glucosidase inhibitors, Thiazolidinediones, 
Dipeptidyl peptidase-4 inhibitors, Sodium glucose co-transporter-2 inhibitors, 
injectable GLP-1 agonists and Insulin) are prescribed when metformin effectivity 
wanes or due to adverse effects (Marín-Peñalver et al., 2016). In South Africa, health 
inequalities cause disparities in the availability, accessibility and affordability of 
diabetes medication. Medicines are often not available leading to poor health 
outcomes. A study in an urban community in the Western Cape reported that only 
38.6% of people with T2DM were on treatment, and of these, only 25.5% had fasting 
glucose values < 6.0 mmol/L (Peer et al., 2012). The situation is likely to be worse in 
rural settings and in other provinces due to decreased access to care. Uncontrolled 
diabetes is associated with increased risk of complications (Ali et al., 2017). Health 
systems strengthening using locally developed interventions such as ‘Quality Circles’, 
which aim to integrate health care providers, health care systems, communities and 
patients and their families (Maimela et al., 2018), are critical to improve the 
management T2DM and improve health outcomes.  
 
5.4 Effective and cost-effective interventions 
The Delphi process, a forecasting method based on responses from a panel of 
experts, was used to rank interventions to prevent and manage diabetes in LMICs (Ali 
et al., 2017). Prevention and management interventions that were recommended 
include blood pressure control among people with diabetes, which was considered a 
high priority and found most feasible and very cost-effective (Ali et al., 2017). Care 
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management to support risk factor control and lifestyle interventions to prevent 
diabetes among high risk individuals were also considered highly effective and cost-
effective. Lifestyle interventions are likely to offer the greatest long-term likelihood to 
slow the growth of diabetes globally, however, implementing them are challenging. To 
achieve these interventions, the following priority actions and approaches were 
recommended: a) targeted screening to detect persons with prediabetes and diabetes, 
espoused in guidelines and policy, and  ensuring that the health system has adequate 
capacity to handle the concomitant health needs of such detection; b) facilitation of 
physical and financial access to essential medication to treat diabetes and vascular 
risks in diabetes, as well as access to laboratory testing for monitoring related markers; 
c) prevention and care services in clinical and non-clinical settings, such as community 
halls and work places, by non-clinical staff such as lifestyle coaches or community 
health workers; and d) research to address key knowledge and best-practice gaps, 
including standardised measurements, and why certain interventions work and others 
are not considered effective and cost-effective (Ali et al., 2017).  
 
In South Africa, early detection of retinopathy and appropriate management can 
prevent blindness (Hofman, Cook & Levitt, 2014). Further, these authors showed that 
screening using a mobile retinal camera is highly cost-effective, with its costs and 
follow-up treatment being less than the expense of a one-year disability grant. In 2017, 
Priceless SA, a research unit in the School of Public Health at the University of 
Witwatersrand provided evidence that fiscal measures such as taxation of sugary 
drinks is a cost-effective method with potential to decrease the health burden of T2DM 
in South Africa (Priceless SA, 2017).   
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6. SYSTEMATIC REVIEWS 
Systematic reviews are at the apex in the hierarchy of epidemiological studies and is 
considered the best available evidence for decision-making (Mallett et al., 2012). The 
review process involves a systematic, transparent and predefined method of data 
collection and study appraisal. Results are synthesised as a meta-analysis, depending 
on the heterogeneity between included studies, or may be described narratively. 
Although systematic reviews were originally developed to evaluate interventions, they 
have been adapted to assess observational studies with the concomitant adaptation 
of tools to appraise studies (Hoy et al., 2012; Murad et al., 2017). Despite their 
increased popularity, the systematic review process may be flawed by poor design 
and execution of the review process. Although these may be overcome, reviews have 
fundamental limitations due to the quality of included studies, lack of raw data and 
reliance on author’s self-report (Mallett et al., 2012; Møller, Ioannidis & Darmon, 2018). 
Despite these disadvantages, a well-conducted systematic review may be useful to 




The literature review has provided an overview of T2DM, briefly describing the different 
types of diabetes and the burden globally and in Africa and South Africa.  I highlighted 
risk factors in South Africa and listed the challenges of measuring T2DM prevalence 
in epidemiological studies. Lastly, I described prevention and management strategies 
for T2DM, and pointed to priority actions and approaches to achieve such prevention 
and management of T2DM. Type 2 diabetes is an escalating public health crisis, 
particularly in South Africa, due to health inequalities and the already overburdened 
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and under-resourced health system. Moreover, given the country’s population growth, 
population ageing, and little success in preventing obesity at the population level 
(National Department of Health, 2019), the most important risk factor for T2DM (NCD 
Risk Factor Collaboration, 2016), such escalation seems inevitable. Urgent and 
effective population-level interventions are required to delay the onset or prevent 
T2DM. In addition, a strong drive in primary care to identify all people at high risk of 
developing T2DM with available and reliable measures, together with available and 
effective drug supply, such as metformin, and providing advice and take-home 
information towards inducing and maintaining changes in lifestyle (NCD Risk Factor 
Collaboration, 2016), may be an interim approach until effective population-level 
interventions deliver successful detection, prevention and management of T2DM. 
Such initiatives in South Africa, however, are hampered by the lack of recent and 
reliable national prevalence data to inform health policy and planning. There is an 
urgent need for representative epidemiological data on the prevalence of T2DM in 
South Africa. To address the paucity in national T2DM prevalence data in South Africa, 
it would be valuable to undertake a systematic review to identify, appraise, collate and 
synthesise all studies that report T2DM prevalence. Such a review has not been 
undertaken previously, and Part C and D of this thesis address this need.   
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1. ABSTRACT 
Objectives The aim of this study was to estimate the prevalence of type 2 diabetes 
mellitus (T2DM), impaired glucose tolerance (IGT), impaired fasting glucose (IFG) and 
undiagnosed T2DM in South Africa. 
Study design Systematic review of studies reporting T2DM prevalence in South Africa 
published between January 1997 and May 2019. PubMed, Scopus, Web of Science 
and African Index Medicus, grey literature and references of included studies were 
searched. Two reviewers independently selected studies and the quality of included 
studies was appraised using a web-based system, the Burden of Disease Review 
Manager (BODRevMan) adapted from the risk of bias tool for population-based 
studies and the Newcastle-Ottawa Scale for assessing the quality of non-randomised 
studies. 
Setting All studies conducted in South Africa irrespective of geographical location.  
Participants All South Africans irrespective of population group, age and gender.   
Outcomes The primary outcome was prevalence of T2DM. The secondary outcomes 
were IGT, IFG and undiagnosed T2DM.  
Results A total of 1782 articles were identified, 1651 titles and abstracts were 
screened for eligibility, full-text articles requested for 55, of which 15 were included in 
the study. Heterogeneity across studies did not allow for a meta-analysis and a pooled 
estimate, thus results are described narratively. Some studies failed to report key 
methodological elements, which limited our ability to accurately appraise study quality.  
Conclusions We report a high prevalence of glucose intolerance in South Africa. 
Moreover, we highlight the paucity of nationally representative T2DM prevalence data, 
and the need for well-designed epidemiological studies that use best-practice, uniform 
diagnostic methods to assess prevalence. Collaboration between public health 
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scientists, diabetes specialists and policy makers are essential to enable the collection 
of reliable national epidemiological data which can guide policy and planning towards  
diabetes prevention and management strategies.  
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2. STRENGTHS AND LIMITATIONS 
• The first systematic review of type 2 diabetes mellitus (T2DM), impaired glucose 
tolerance (IGT), impaired fasting glucose (IFG) and undiagnosed T2DM 
prevalence in South Africa. 
• A comprehensive synthesis of all available T2DM prevalence data in South Africa 
using rigorous systematic review methods, standardised risk of bias tools and 
adhering to Preferred Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) guidelines. 
• Inadequate reporting of methods limited risk of bias and quality assessment of 
studies, while choice of study population limited generalisability of the findings.  
• Gaps in diagnostics for T2DM may result in over- or underestimation of prevalence.  
• Heterogeneity across studies did not allow a meta-analysis for a pooled estimate, 
nor the analyses and description of trends over time. 
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3. INTRODUCTION 
Diabetes affects approximately 451 million adults worldwide, with projections of 693 
million cases by 2045 [1]. The largest increase is predicted for Africa where in 2017, 
15.5 million adults had diabetes, with 69.2% of people unaware of their diabetic status. 
Africa is already grappling with high rates of infectious diseases thus diabetes poses 
a serious health and economic burden to these already overburdened and under-
resourced health systems [1]. To achieve the United Nations Sustainable 
Development Goal 3, which aims to reduce premature mortality from non-
communicable diseases (NCDs) by a third by 2030 [2], requires urgent action and 
effective intervention strategies to combat the rising diabetes epidemic in Africa. In 
Africa, as in other parts of the world, type 2 diabetes mellitus (T2DM) represents over 
90% of diabetes cases [3].  
 
South Africa is ranked as an upper-middle income country [4] and is the second largest 
economy in Africa. Despite this, it is plagued by high economic and health inequalities 
due to years of racial and gender discriminatory policies, which have led to a sub-
optimal health system with health outcomes often worse than those in poorer countries 
[5]. South Africa has a unique quadruple disease burden characterised by high rates 
of Human immunodeficiency virus (HIV)/Acquired immunodeficiency syndrome (AIDS) 
and Tuberculosis (TB), non-communicable diseases, maternal and childhood 
mortality, and injury-related disorders [6]. The prevalence of T2DM has almost doubled 
from 5.5% in 2000 to 9% in 2009 [7,8], and although these estimates were based on 
robust modelling methods, they probably underestimate the current disease burden 
as risk factors of T2DM have significantly increased in recent years. Rapid 
urbanisation characterised by the adoption of unhealthy energy-dense diets and 
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physical inactivity have contributed to the steadily increasing obesity epidemic, with 
69% of women and 39% of men in South Africa being overweight or obese [9]. Excess 
bodyweight is estimated to account for 87% of T2DM cases in South Africa [10], while 
HIV/AIDS and antiretroviral treatment (ART) is associated with premature ageing, 
metabolic dysfunction, increased life expectancy and risk for T2DM [11–15]. It is 
estimated that a staggering 20% of people between 15 and 64 years of age in South 
Africa are HIV infected [16]. Recent studies estimate the T2DM age-adjusted 
prevalence at 13.1% [17] or 26.3% [18] depending on population group. Furthermore, 
high rates of glucose intolerance, which is associated with a 5-12 times higher annual 
risk of developing T2DM compared to the general population [19], and undiagnosed 
diabetes have been reported [17,18], demonstrating a high overall burden of 
dysglycaemia. Mortality directly attributable to diabetes, increased by 29% between 
1997 and 2012 [20], this increase most probably continuing. In 2009, it was estimated 
that diabetes accounted for about 8000 new cases of blindness and 2000 new cases 
of amputations annually in South Africa [8], while 14% of ischaemic heart disease, 
10% of stroke, 12% of hypertensive disease and 12% of renal disease in South Africa 
is attributed to diabetes [7].  
 
Reliable national epidemiological data on T2DM prevalence are required to inform 
health policy and planning to facilitate appropriate prevention and management 
strategies. Two national surveys have been conducted [21,22], however 
methodological concerns about these studies (sub-optimal response rates and 
diagnostic tests) and the lack of generalisable data from research studies [17,18,23–
28] prompted this review. The aim of this systematic review is to estimate the T2DM 
prevalence in South Africa between 1997 and 2018. The prevalence of IGT, IFG and 
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undiagnosed diabetes will also be assessed to estimate the overall prevalence of 
glucose intolerance in South Africa. This data could inform policy and planning for 
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4. METHODS 
This systematic review was conducted adhering to the published protocol [29] and is 
registered with the Prospective Register of Systemic Reviews (PROSPERO): 
CRD42017071280. The review adheres to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Part D-Appendix) [30].  
 
4.1 Literature Search 
Four major databases (PubMed, Scopus, Web of Science and African Index Medicus) 
were searched for studies on the prevalence of T2DM in South Africa, published 
between January 1997 and May 2019. These databases were selected as they were 
comprehensive, indexing articles from several disciplines from notable journals, and 
grey literature such as theses/dissertations, technical reports, etc. that contain 
information specific to Africa [31]. Search terms included keywords and medical 
subject headings (MeSH) such as diabetes mellitus, T2DM, glycosylated 
haemoglobin, diagnosis, IGT, IFG and undiagnosed diabetes including corresponding 
synonyms and associated terms for each item. The search strategy is shown in 
Supplementary Table 1 (Part D-Appendix) and was adapted for each database, and 
references were managed in EndNote X7.0.1 (Thomson Reuters). Reference lists of 
eligible studies were searched to identify studies for possible inclusion; we contacted 
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4.2 Eligibility criteria 
Population-based surveys, cross-sectional studies and prospective or retrospective 
cohort studies were included if they were conducted in South Africa and had more 
than 100 participants regardless of gender, population group [32], age, socioeconomic 
and educational background, and reported the primary outcome (T2DM prevalence) 
according to World Health Organization (WHO) diagnostic criteria [33–35]. Population 
group was classified according to previously defined apartheid categories of Black 
African, Coloured, Indian/Asian, White and other, which was introduced into the new 
birth death notification in 1998 to track health inequalities [32]. Only individuals aged 
25 years and older were included for T2DM prevalence.   
 
4.3 Outcome measures 
Primary outcome: 
T2DM defined as fasting plasma glucose (FPG) ≥7.0 mmol/L, 2-hour oral glucose 
tolerance test (OGTT) plasma glucose ≥11.1 mmol/L, glycated haemoglobin (HbA1c) 
≥6.5% (48 mmol/mol) or self-reported use of oral diabetes drugs.  
Secondary outcomes: 
IGT (FPG <7.0 mmol/L and 2-hour OGTT plasma ≥7.8 mmol/L and <11.1 mmol/L), 
IFG (>6.1 mmol/L and < 7.0 mmol/L); and 
Undiagnosed T2DM defined as the number of new cases of diabetes as a proportion 
of the total sample [34,35,35].  
 
4.4 Study selection, quality assessment and data extraction 
After removal of duplicates, two reviewers (CP, VPvW or ET) independently screened 
titles and abstracts to select full-text articles for inclusion. The two reviewers assessed 
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each included study for risk of bias using a web-based standardised checklist for 
systematic review of observational epidemiological studies, Burden of Disease  
Review Manager (BODRevMan) developed by the South African Medical Research 
Council [31], that was adapted from the risk of bias tool for population-based studies 
[36] and the Newcastle-Ottawa Scale for assessing the quality of non-randomised 
studies [37,38] (Supplementary Table 2, Part D-Appendix). Two authors 
independently extracted and recorded data using BODRevMan. Data extracted 
included date of publication and details of study design, location, population 
characteristics, response rates, T2DM, IGT, IFG and undiagnosed T2DM prevalence, 
and case definition as reported in the study. When not reported, depending on the 
study design, and if the necessary information was available 95% Confidence Intervals 
(95% CI) were calculated in STATA® version 14.0 (StataCorp, College Station, TX, 
USA). For national surveys (South African National Health and Nutrition Examination 
Survey (SANHANES) and South African Demographic Health Survey (SADHS)), data 
were reanalysed taking design effect into consideration. Comorbid disease (HIV/AIDS 
and TB) was documented when reported. Corresponding authors were contacted 
when further clarification/more information was required. Raw data from studies and 
national surveys were recalculated to only include prevalence in individuals 25 years 
and older. Disagreements or uncertainties at each stage of the review process 
(screening, risk of bias assessment and data extraction) were resolved by discussion 
and consensus between the two reviewers, or with a third reviewer if disagreement 




78 | P a g e  
 
4.5 Data synthesis and analysis 
Clinical heterogeneity was explored by looking at the characteristics of participants, 
method of diagnosis and case definitions in the study. A meta-analysis nor meta-
regression were possible due to extensive heterogeneity of included studies with 
respect to population group, study design and geographical location. Thus, a narrative 
synthesis of the included studies was conducted. Studies were too diverse to 
undertake a meaningful subgroup analysis. Results are displayed using tables and 
forest plots (Excel, Microsoft Office 15) as appropriate. 
 
4.6 Confidence in cumulative evidence 
The strength of evidence was assessed using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) method [39,40], which scores 
studies as very low, low, moderate, or high based on methodological flaws within the 
included studies, consistency of results across diverse studies, precision of estimates 
and publication bias.  
 
4.7 Patient and public involvement 
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5. RESULTS 
5.1 Selected studies 
Figure 1 displays the flow diagram for the review process. A total of 1782 articles were 
identified with 1651 records left after removal of duplicates. Titles and abstracts were 
screened for eligibility, after which 55 were selected for full-text review, of which 15 
studies met the inclusion criteria and were included in the systematic review. Studies 
were conducted between 1997 and 2016, and in different population groups, 
provinces, locations (urban vs. rural), age groups and using different diagnostic tests 
(FPG, OGTT or HbA1c) according to WHO criteria [33–35]. The studies included two 
national surveys SANHANES and SADHS, and 10 community- and 3 facility-based 
research studies. The national surveys included all population groups, eight studies 
were conducted in Black Africans, three were conducted in Coloureds, one in Indians 
and one study was conducted in a population consisting of both Black African and 
Coloured individuals. Most studies were conducted in urban settings (six urban, two 
peri-urban, four rural and three studies were conducted in both urban and rural 
settings). The ages of participants across studies varied to include those between 
certain age bands only, or everyone aged 15 and above. Raw data from these studies 
were recalculated to only include those aged 25 years and older. Study characteristics 
are listed in Supplementary Table 3 (Part D-Appendix). In most studies reporting was 
sub-optimal, which limited risk assessment. Furthermore, a few studies did not report 
the data in the required format or failed to report 95% CIs. Authors were contacted 
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5.2 Type 2 diabetes prevalence  
Studies that report the prevalence of T2DM are presented in Figure 2. Although some 
studies reported age-adjusted prevalence, the crude prevalence was used in the forest 
plot to facilitate comparability between studies. The prevalence of T2DM ranged from 
3.0% to 35.2% according to population group, age, geographic location and diagnostic 
test. A high prevalence of T2DM was reported in Indians (35.2% [43]) and Coloureds 
(28.2% [18], 19.3% [41] and 24.6% [42]). The prevalence of T2DM in Black Africans 
ranged from 3.0% in a small study conducted amongst factory workers in the Eastern 
Cape [25] to 12.1% [17] and 16.5% [44] in urban populations from the Western Cape 
and KwaZulu Natal, respectively. SANHANES reported a prevalence of 14.7% [22] 
and SADHS a prevalence of 14.9% [21]. A higher prevalence was reported in rural 
compared to urban settings in the Free State (7.9% vs. 4.3% [45]) (Supplementary 
Table 3). It was not possible to compare diagnostic test across the 15 studies since 
they were conducted in different population groups, ages and settings. However, two 
studies compared the performance of different diagnostic tests (Supplementary Table 
4, Part D-Appendix) [44,46]. Hird et al. [44] reported a similar prevalence irrespective 
whether FPG (11.8%), OGTT (10.3%) or HbA1c (12.9%) was used, whereas Oni et al 
[46] reported a higher prevalence of T2DM and impaired glucose regulation using 
HbA1c (8.2% and 39.5%) compared to FPG (4.1% and 10.6%) and OGTT (3.3% and 
10.6%). These higher rates of diagnosis using HbA1c was particularly evident in TB 
positive individuals [46]. Eight studies reported T2DM prevalence estimates for 
females and males (Figure 3). Prevalence was consistently higher in females 
compared to males, although the increase in two studies were small [25,26]. Seven 
studies reported T2DM prevalence across different age groups. As expected, all 
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studies reported that prevalence increased with age (Figure 4), with an extremely high 
prevalence (59.8%) observed in Indians between 55 and 64 years of age [43]. 
 
5.3 Impaired glucose tolerance, impaired fasting glucose and undiagnosed 
diabetes 
The prevalence of IGT and IFG mirrored T2DM (Figure 5A), with the highest rates 
reported in Indians and Coloureds [18,42,43]. Comparatively lower rates were 
reported in Black Africans (0.9%-10.7%) [17,25,26,44,46], although a high prevalence 
(20.3%) was reported in Black African females in an urban community [47]. The 
prevalence of undiagnosed T2DM ranged from 2.7% to 18.1% (Figure 5B). The 
highest prevalence (18.1%) was observed in Coloureds [18].  
 
5.4 Tuberculosis/Human immunodeficiency virus 
Although not representative, prevalence data for studies conducted during TB and HIV 
comorbidity were included for informative purposes and are illustrated in Figure 6. Two 
studies, which were both conducted in rural settings in Limpopo reported a prevalence 
of 4.5% in HIV positive [48] and 12.5% HIV negative [49] individuals, although the 
former was conducted in a health centre, while the latter was community based. One 
study, which was conducted in a TB clinic in the Western Cape reported T2DM 
prevalence in both HIV negative and positive individuals [46]. Prevalence of T2DM 
was higher in HIV negative (16.0%) compared to HIV positive (8.9%) individuals, and 
in TB positive (12.6%) compared to TB negative (10.1%) patients (Figure 6, 
Supplementary Table 3, Part D-Appendix).  
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5.5 Publication bias  
We attempted to minimise publication bias in this review in a number of ways. A 
comprehensive search, which included consulting with experts to identify grey or 
unpublished literature was conducted. Four major databases were searched [31]. 
Reference lists of articles were screened to identify potentially eligible studies. At least 
two review authors independently scrutinised and selected articles for inclusion in the 
review using pre-specified eligibility criteria, assessed risk of bias and extracted data.  
 
5.6 GRADE 
The overall level of evidence as qualified with GRADE was low as shown in 
Supplementary Table 5 (Part D-Appendix) due to limitations in study design, poor 
response rate, unclear risk of bias, methodological limitations, more studies reporting 
on female population creating gender bias which negatively affects generalisability and 
wide confidence intervals. 
 
  
















































Records identified through 
database searching 
(n = 1751) 
Records identified through 
experts and other sources 
       (n = 31) 
Studies excluded (1596) 
No assessment of T2DM 
Participants with T2DM excluded 
Study published before 1997 
Used secondary data 




(titles & abstracts) 
(n = 1651) 
Full-text articles excluded with 
reasons: 
Secondary data, N=4 
Data reported in another study, N=2 
Can’t calculate T2DM estimates, N=15 
Did not meet inclusion criteria 
(secondary data/pre-1997/random 
glucose), N=8 
Population unsuitable to calculate, T2DM 
prevalence, N=11 
Full-text articles 
assessed for eligibility 
(n =55) 
Studies assessed for risk of 
bias and included in the 
narrative review 
(n =15) 
Duplicate records excluded 
(131) 

















Figure 2. Forest plot of type 2 diabetes prevalence.  
Note: Data are represented as the crude prevalence and 95% CI. Prevalence was measured in females (Crowther et al. 2012 
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Figure 5. Forest plot of impaired glucose tolerance and impaired fasting glucose (A) 
and undiagnosed diabetes (B).  
Note: Prevalence was measured in females (Crowther et al. 2012 [47]) only. *Data were recalculated to include individuals 25 
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Figure 6. Forest plot of type 2 diabetes prevalence in TB and HIV studies.  
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6. DISCUSSION 
This systematic review shows that the prevalence of T2DM in South Africa varies 
according to population group, age, gender, diagnostic test and comorbid disease, 
highlighting the challenges of measuring T2DM prevalence [50]. The heterogeneity of 
studies did not allow for a meta-analysis to calculate a pooled estimate or do a trend 
analysis. Nonetheless, we provide compelling evidence that glucose intolerance 
(T2DM, IGT, IFG and undiagnosed T2DM) in South Africa is high and poses a 
significant threat to the already overburdened and under-resourced health system.  
 
The greatest source of heterogeneity in T2DM prevalence was population group and 
reflects NCD mortality rates, which are highest for Indians, followed by Coloureds and 
lowest in Black Africans [20]. Black Africans and Coloureds are confronted with the 
highest dual burden of NCDs and infectious disease, while mortality in Indians and 
Whites are mainly due to NCDs [20]. Population group differentials are postulated to 
be due to “the legacy of Apartheid and the state of health transition”. These differences 
could be ascribed to socio-economic status and/or genetics. Differences in insulin 
resistance, the main pathophysiology of T2DM, have been reported between Black 
African and White South African women [51,52], while Indians may be genetically 
predisposed to T2DM through innate susceptibilities in β-cell dysfunction [53]. 
 
The positive correlation between age and T2DM prevalence is consistent with 
scientific evidence linking increasing age with progressive glucose intolerance [54]. 
Demographic transition and population ageing due to the widespread implementation 
and success of ART regimens and improvements in access to care [14,15], will thus 
undeniably increase the prevalence of T2DM and burden on our health system. In 
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2015, a systematic review on diabetes prevalence in Africa reported an overall 
prevalence of 13.7% amongst individuals aged 55 years and older [38]. Alarmingly, 
most of the studies in South Africa report an almost two-fold higher prevalence in this 
age group [17,21,22,42,44]. Rapid urbanisation and adoption of unhealthy lifestyles 
are considered major drivers of the T2DM epidemic [38]. Urban/rural disparities were 
not markedly apparent in our review and are consistent with findings from urban and 
rural communities in South Africa and Zambia [55]. Rates of modifiable risk factors 
(obesity, physical activity and smoking) in rural communities are high [56] and could 
partly account for the high prevalence of T2DM in these communities. The prevalence 
of T2DM in females was higher than in males, possibly due to increased insulin 
resistance [57] and obesity [9] in South African women compared to their male 
counterparts. Furthermore, gender bias could have affected results since most studies 
had more female than male participants, a common caveat in epidemiological studies. 
The WHO has recently recommended gender-based interventions against NCDs [58], 
signifying the importance of gender disparities in disease.  
 
Diagnosis of T2DM is contentious, with no single preferred diagnostic test. The OGTT, 
which measures glucose concentrations two hours after ingesting 75-g of glucose is 
considered the gold standard for T2DM diagnosis, however, is cumbersome to 
perform. The FPG and HbA1c tests are often employed as diagnostic tests in place of 
the OGTT depending on health care facility and resources [59]. The two included 
studies that compared diagnostic tests, showed no significant difference between 
OGTT and FPG [44,46], in contrast to previous studies from South Africa [26,42,59], 
Africa [38] and globally [60] that report that the use of FPG alone misses a significant 
number of diabetes cases, and motivates for the use of OGTT. Differences between 
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the OGTT and FPG test may reflect population differences due to disease stage and 
pathophysiology, thus both tests are recommended. Importantly, OGTT is the only test 
able to detect IGT, the major pathophysiology associated with T2DM and essential to 
estimate overall burden of glucose intolerance. Discrepancies between diagnostic 
tests were mainly evident when measuring HbA1c, particularly in TB patients [46]. The 
HbA1c test also fared poorly in a large international pooled analysis of population-
based health surveys [48], and physiological differences related to red blood cell 
turnover (anaemia and iron status) has been suggested to contribute to regional 
variations. Thus, although the test does not require fasting and is clinically more 
convenient and acceptable to patients, poor sensitivity and false positivity in TB 
patients limit its use in South Africa. Studies to identify appropriate HbA1c cut-offs in 
South Africa [59] or develop novel diagnostic tests that are applicable to our population 
[63–66] are required. 
 
The prevalence of T2DM was lower in HIV negative compared HIV positive individuals, 
in contrast to the widely held view that HIV infection and ART treatment increases the 
risk for T2DM [12,13]. Similar findings were reported in other studies in South Africa 
[55,67], and are thought to be due to decreased adiposity during HIV infection or 
improved health awareness as part of ART programs. Alternatively, HIV infection could 
increase disease severity resulting in early mortality, which would translate to 
decreased prevalence. This hypothesis requires further exploration. 
 
In conclusion, we report a high prevalence of glucose intolerance in South Africa. 
Moreover, we highlight the heterogeneity of T2DM prevalence across population 
group, age, gender, setting, diagnostic test, and HIV/AIDS and TB status, which all 
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contribute to the challenges of measuring prevalence and the paucity of nationally 
representative T2DM prevalence data. Well-designed epidemiological studies that use 
best-practice, uniform diagnostic methods to assess prevalence are urgently required. 
Collaboration between public health scientists, diabetes specialists and policy makers 
are essential to enable the collection of reliable national epidemiological data to guide 
policy and planning towards facilitating appropriate diabetes prevention and 
management strategies. Political commitment is essential to prioritise and allocate 
resources to alter the trajectory of T2DM.  
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Supplementary Table 1. PubMed search strategy  
 Search Query 
#4 Search ((#3 NOT (animals[mh] NOT humans[mh]))) AND 
(“1997/01/01”[Date-Publication] : “2019/05/28”[Date-Publication]) 
#3 Search (#1 AND #2) 
#2 Search (South Africa[mh]OR“South Africa*”[tiab] OR RSA[tiab] OR Africa, 
Southern[mh:noexp] OR Southern Africa[tiab]) 
#1 Search (Diabetes[Mesh] OR Diabetes mellitus[Mesh] OR type 2 diabetes 
mellitus[Mesh] OR type 2 diabetes[Mesh] OR Diabetes mellitus, type 
2[Mesh] OR Diabetes, type 2[Mesh] OR hyperglycemia[Mesh] OR blood 
glucose[Mesh] OR Hemoglobin A, glycosylated[Mesh] OR Glycosylated 
hemoglobin OR diagnosis OR impaired glucose tolerance OR impaired 
fasting glucose OR undiagnosed diabetes 
 
The PubMed search strategy was adapted for optimal searching in the other 
databases.  
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Supplementary Table 2. Quality assessment criteria for prevalence studies 
Domain Criteria Question Score 
External validity 
Representativeness 
Was a sample size calculation conducted and is it 
adequate? 1 
Is the target population a close representation of the 
national population in relation to relevant variables? 1 
Was the sampling frame a true or close representation of 
the population? 1 
Was a form of random selection used to select the 
sample? Was the sampling method appropriate for the 
research question? 2 
Non-response bias 
Were there similarities between participants and non-
participants in relation to demographic characteristics? 1 
Was the overall/response rate of the study reported? 1 
What was the overall/response rate for the study? 1 
Was the overall/response rate adequate for the study? 
Excellent ≥80%, Average 60-79%, Poor <60% 1 
Internal validity 
Case definition 
Were the cases classified using the ICD codes or was an 
acceptable case definition used? What is the case 
definition? 1 
Were the study instruments used to measure the 
parameter of interest shown to have reliability and validity 
in this study or a previous study? 2 
Data collection 
Were data collected directly from the participants or is a 
proxy was used, was it appropriate? 1 
Was the same mode of date collection used for all 
participants for the condition of interest? 1 
Uncertainty of estimation 
Was the parameter of interest reported with uncertainty, 
i.e. Standard deviation (SD), Standard Error (SE) or 95% 
Confidence Interval (CI)? 1 
Appropriateness of time 
factor for outcome measure 
Was the length of recall period for the parameter of interest 
appropriate to ascertain outcome/exposure? 2 
Appropriateness of 
numerator and denominator 
in calculation of estimate 
Were the numerator and the denominator for the 
parameter of interest appropriate? If not, can these be 
extracted to recalculate the parameter of interest? 2 
Confounding 
Were potential confounding factors sought and controlled 
for? 1 
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Risk of bias was assessed using a web-based standardised checklist for systematic 
review of observational epidemiological studies, Burden of Disease Review Manager 
(BODRevMan) developed by the South African Medical Research Council [31], that 
was adapted from the risk of bias tool for population-based studies [36] and the 
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Age-adjusted 
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1Population group was classified according to previously defined apartheid categories of Black African, Coloured, Indian/Asian, White 
and other, which was introduced into the new birth death notification in 1998 to track health inequalities [32]. 
2Number of participants for case definition 
3Numbers in age groups not reported, not possible to calculate 95% CI 
4Study conducted in females only 
5Study conducted in HIV positive individuals only 
6Study conducted in HIV negative individuals only 
ADA: American Diabetes Association; EC: Eastern Cape; FPG: Fasting plasma glucose; HbA1: Glycated haemoglobin; HIV: 
Human immunodeficiency virus; IFG: Impaired fasting glucose; IGT: impaired glucose tolerance; IGR: impaired glucose regulation; 
KZN: KwaZuluNatal; NR: Not reported; OGTT: Oral glucose tolerance test: TB: Tuberculosis; T2DM: type 2 diabetes mellitus; WC: 
Western Cape; WHO: World Health Organization. 
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Supplementary Table 4. Included studies that compared different diagnostic tests 
 Hird 2006 [44] Oni 2017 [46] 
Diagnostic 
Test 



































FPG: Fasting plasma glucose; HbA1c: Glycated Haemoglobin; IGR: Impaired 
glucose regulation; NR: Not reported; OGTT: Oral glucose tolerance test, TB: 
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Supplementary Table 5. Level of evidence as qualified with GRADE  

















Prevalence of type 2 diabetes (assessed with: The following criteria was used to diagnosed type 2 diabetes: 1. WHO (2006) diagnostic criteria where type 2 diabetes is 
diagnosed either by a physician, fasting blood glucose concentrations ≥7.0 mmol/L, 2-hour oral glucose tolerance test values ≥11.1 mmol/L or self-reported use of oral 
diabetes drugs. 2. Glycated haemoglobin ≥6.5% (48 mmol/mol). ) 
15  observational 
studies  
serious a serious b serious c serious d none  17,461 participants not pooled  
  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) (assessed with: IGT measured using FPG <7.0 mmol/L and 2-hour OGTT plasma ≥7.8 mmol/L and 
<11.1 mmol/L; IFG measured using >6.1 mmol/L and < 7.0 mmol/L) 
12  observational 
studies  
serious a serious b serious c  serious d none  IGT: 5783 participants 
IFG: 6026 participants 
not pooled  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Undiagnosed type 2 diabetes (assessed with: • T2DM defined as fasting plasma glucose (FPG) ≥7.0 mmol/L, 2-hour oral glucose tolerance test (OGTT) plasma glucose ≥11.1 
mmol/L, glycated haemoglobin (HbA1c) ≥6.5% (48 mmol/mol)) 
7  observational 
studies  
serious a serious b  serious c serious d none  5445 participants not pooled  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
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Explanations 
a. Downgraded by 1 because of limitations in studies design, poor response rate and unclear of risk of bias  
b. Downgraded by 1 because of methodological limitations  
c. Sampling bias and more studies reporting on female population creating gender bias which negatively affects generalisability  
d. Downgraded by 1 because of unclear of risk of bias, and wide confidence intervals  
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Statistical formula 
Formula for calculating confidence intervals in STATA (StataCorp 14.0, College 
Station, Texas, USA) 
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INSTRUCTIONS TO AUTHORS 
BMJ Open 
BMJ Open is an open access journal dedicated exclusively to publishing medical research. 
The journal aims to provide rapid publication of research across a range of medical 
disciplines and therapeutic areas, through a continuous publication model. As well as 
publishing definitive articles, including small and specialist studies, BMJ Open will consider 
protocols and pilot studies. See here for more information on what we publish. Submissions 
will only be published after peer review, and reviewers’ comments will be published 
alongside accepted manuscripts. 
Research submissions should have a clear, justified research question. 
We strongly encourage you to register your study. Prospective registration is mandatory for 
any clinical trials. Acceptable registries for trials are clinicaltrials.gov along with those 
listed here. We recommend Prospero for registration of systematic reviews. 
All articles should include the following: 
• The article title should include the research question and the study design. Titles 
should not declare the results of the study. 
• A structured abstract (max. 300 words) including all the following where appropriate 
(please note that for RCTs there is a specific CONSORT extension for abstracts):  
o objectives: clear statement of main study aim and major hypothesis/research 
question 
o design: e.g. prospective, randomised, blinded, case control 
o setting: level of care e.g. primary, secondary; number of participating 
centres. Generalise; don’t use the name of a specific centre, but give 
geographical location if important 
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o participants: numbers entering and completing the study; sex and ethnic 
group if appropriate. Clear definitions of selection, entry and exclusion 
criteria 
o interventions: what, how, when and how long (this can be deleted if there 
were no interventions) 
o primary and secondary outcome measures: planned (i.e. in the protocol) and 
those finally measured (if different, explain why) – for quantitative studies 
only 
o results: main results with (for quantitative studies) 95% confidence intervals 
and, where appropriate, the exact level of statistical significance and the 
number need to treat/harm. Whenever possible, state absolute rather than 
relative risks 
o conclusions: primary conclusions and their implications, suggest areas for 
further research if appropriate. Do not go beyond the data in the article 
o where applicable, trial registration: registry and number (for clinical trials 
and, if available, for observational studies and systematic reviews) 
• An Article Summary, placed after the abstract, consisting of the heading ‘Strengths 
and limitations of this study’, and containing up to five short bullet points, no longer 
than one sentence each, that relate specifically to the methods. They should not 
include the results of the study. 
• The original protocol for the study, as a supplementary file. 
• A funding statement, preferably worded as follows. Either: ‘This work was 
supported by [name of funder] grant number [xxx]’ or ‘This research received no 
specific grant from any funding agency in the public, commercial or not-for-profit 
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sectors’. You must ensure that the full, correct details of your funder(s) and any 
relevant grant numbers are included. 
• A competing interests statement. See the BMJ Author Hub for details on what to 
include as competing interests. 
• Articles should list each author’s contribution individually at the end; this section 
may also include contributors who do not qualify as authors. Please visit the ICMJE 
website for more information on authorship. 
• Any checklist and flow diagram for the appropriate reporting statement, e.g. 
STROBE (see below). 
• A patient consent form: any article that contains personal medical information 
about an identifiable living individual requires the patient’s explicit consent before 
we can publish it. We will need the patient to sign our consent form, which requires 
the patient to have read the article. This form is available in multiple languages. 
• A data sharing statement, such as: “Technical appendix, statistical code, and dataset 
available from the Dryad repository, DOI: [include DOI for dataset here]. 
• Word count, we recommend your article does not exceed 4000 words, with up to 
five figures and tables. This is flexible, but exceeding this will impact upon the 
paper’s ‘readability’. Authors are encouraged to submit figures and images in colour 
– there are no colour charges. We require that you upload your figures as separate 
files rather than embedding them in the manuscript. 
• Supplementary and raw data can be placed online alongside the article although we 
prefer raw data to be made publicly available and linked to in a suitable repository 
(e.g. Dryad, FigShare). We may request that you separate out some material into 
supplementary data files to make the main manuscript clearer for readers. 
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We also recommend, but do not insist, that the discussion section is no longer than five 
paragraphs and follows this overall structure (you do not need to use these as subheadings): 
a statement of the principal findings; strengths and weaknesses of the study; strengths and 
weaknesses in relation to other studies, discussing important differences in results; the 
meaning of the study: possible explanations and implications for clinicians and 
policymakers; and unanswered questions and future research. 
At upload you will be asked to choose one general subject area that applies to your article – 
it will be published under this banner on the main table of contents. You will also be asked 
to select further subject headings to be used for the ‘Browse by topic’ section, and specific 
keywords for help with identifying reviewers. 
Following the lead of The BMJ and its patient partnership strategy, BMJ Open is encouraging 
active patient involvement in setting the research agenda. As such, we require authors of 
Research Articles to add a Patient and Public Involvement statement in the Methods 
section. Please see more details above. 
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PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section and topic Item No Checklist item Part A Protocol No. 
ADMINISTRATIVE INFORMATION  
Title:    
 Identification 1a Identify the report as a protocol of a systematic review 14 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such  
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number 16 
Authors:    
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical 
mailing address of corresponding author 
14 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 26 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify 
as such and list changes; otherwise, state plan for documenting important protocol amendments 
N/A 
Support:    
 Sources 5a Indicate sources of financial or other support for the review 26 
 Sponsor 5b Provide name for the review funder and/or sponsor  
 Role of sponsor or 
funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol  
INTRODUCTION  
Rationale 6 Describe the rationale for the review in the context of what is already known 19 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to 
participants, interventions, comparators, and outcomes (PICO) 
20 
METHODS  
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report 
characteristics (such as years considered, language, publication status) to be used as criteria for 
eligibility for the review 
20 
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study 
authors, trial registers or other grey literature sources) with planned dates of coverage 
22 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned 
limits, such that it could be repeated 
23 
Study records:    
 Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 22,24 
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 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) 
through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 
23 
 Data collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done 
independently, in duplicate), any processes for obtaining and confirming data from investigators 
24 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), 




13 List and define all outcomes for which data will be sought, including prioritization of main and 
additional outcomes, with rationale 
21,22 
Risk of bias in 
individual studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether 
this will be done at the outcome or study level, or both; state how this information will be used in 
data synthesis 
24 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 25 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of 
handling data and methods of combining data from studies, including any planned exploration of 
consistency (such as I2, Kendall’s τ) 
25 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-
regression) 
25 
15d If quantitative synthesis is not appropriate, describe the type of summary planned 25 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, 




17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 25 
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important 
clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the 
PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, 
Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 
2015 Jan 2;349(jan02 1):g7647. 
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PRISMA (Preferred Reporting Items for Systematic review and Meta-Analysis) 2009 checklist: recommended items to address in a 
systematic review *  
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  67 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
69 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  72 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
73 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
75 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
76 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
75 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
75 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
76 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
76 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
77 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
77 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  77 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
78 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
78 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
78 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
79 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
107 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  107 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
84,85,86,87 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  107 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  78 
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DISCUSSION  
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
88 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
71,89,90 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  90 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
91 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
 
